Our products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women’s health, and chronic pain conditions.
We continue to innovate in these areas and are extending our innovations into new geographies and high-growth adjacency markets.[/td_text_with_title]
First Patients Enrolled in the FAST Feasibility Study MARLBOROUGH, Mass., July 20, 2015 /PRNewswire/ — Boston Scientific (NYSE: BSX) has initiated a study of the company’s first fully resorbable drug-eluting scaffold system. The Fully Absorbable Scaffold Feasibility Study (FAST) is a prospective, single arm study designed to assess the safety and performance of this next generation […]
Boston Scientific Bronchial Thermoplasty Treatment Recognized By American College Of Allergy, Asthma And Immunology
MARLBOROUGH, Mass., July 9, 2015 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) announces that Bronchial Thermoplasty (BT) delivered by the Alair™ System has received support from the American College of Allergy, Asthma and Immunology (ACAAI). BT is an outpatient procedure proven to reduce asthma attacks in adult patients with severe asthma.1 This demonstrates a growing clinical acceptance among […]
Boston Scientific Initiates Global Study To Assess EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) In Primary Prevention Patients With Low Ejection Fraction MARLBOROUGH, Mass., June 22, 2015 /PRNewswire/ — Boston Scientific (NYSE: BSX) has initiated a worldwide study to evaluate the rate and causes of shocks for patients implanted with the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) for […]
Boston Scientific Announces Definitive Agreement To Acquire American Medical Systems’ Urology Portfolio For Up To $1.65 Billion Combined Business to Advance Patient Care with Leading Solutions Across Major Urology Categories MARLBOROUGH, Mass., March 2, 2015 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Endo International […]